Easywell Biomedicals

Easywell Biomedicals is a Taiwan-based healthcare company active in pharmaceuticals, regenerative medicine, and medical devices. The company develops and commercializes active pharmaceutical ingredients, dosage-form pharmaceuticals, and medical products, and operates U.S. pharmaceutical development and cGMP manufacturing through its Tulex subsidiary. Its disclosed pipeline includes 505(b)(2) reformulations, high-barrier generics, and marketed products such as HH-001 sacubitril/valsartan tablets in China. Easywell also highlights proprietary formulation and drug-delivery technologies focused on bioavailability enhancement and programmable release profiles. The company is publicly traded in Taiwan under stock code 1799 and appears to be expanding through partnerships, licensing, and share-swap M&A activity.